Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
David Lubkowicz
Observed name:
David J Lubkowicz
Institution:
Synlogic (United States)
Observed institutions:
Harvard University,
National University of Singapore,
Synlogic (United States),
Wyss Institute for Biologically Inspired Engineering
ORCID:
0000-0002-1012-4811
Observed ORCID:
0000-0002-1012-4811
OpenAlex ID:
A5083683998
Development of a synthetic live bacterial therapeutic for the human metabolic disease phenylketonuria
2018
·
Vincent M Isabella
, Binh N Ha
, et al.
·
Nature Biotechnology
·
618
Reprogramming Probiotic Lactobacillus reuteri as a Biosensor for Staphylococcus aureus Derived AIP-I Detection
2018
·
David Lubkowicz
, Chun Loong Ho
, et al.
·
ACS Synthetic Biology
·
98
Characterization of an engineered live bacterial therapeutic for the treatment of phenylketonuria in a human gut-on-a-chip
2021
·
M. Tyler Nelson
, Mark R. Charbonneau
, et al.
·
Nature Communications
·
79
PDF
An engineered bacterial therapeutic lowers urinary oxalate in preclinical models and in silico simulations of enteric hyperoxaluria
2022
·
David Lubkowicz
, Nicholas G Horvath
, et al.
·
Molecular Systems Biology
·
56
Transplantability of a circadian clock to a noncircadian organism
2015
·
Anna H. Chen
, David Lubkowicz
, et al.
·
Science Advances
·
41
PDF
The live biotherapeutic SYNB1353 decreases plasma methionine via directed degradation in animal models and healthy volunteers
2024
·
Mylène Perreault
, Jillian Means
, et al.
·
Cell Host & Microbe
·
39
Rational Engineering of Escherichia coli Nissle 1917 as Live Biotherapeutic to Degrade Uremic Toxin Precursors
2024
·
David Lubkowicz
, David L. Hava
, et al.
·
ACS Synthetic Biology
·
10
Activity of Synb1353, an Investigational Methionine-consuming Synthetic Biotic Medicine, in an Acute Nonhuman Primate Model of Homocystinuria
2022
·
Mylene Perreault
, Erik Gerson
, et al.
·
Molecular Genetics and Metabolism
·
4
Sa1654: ENGINEERING SYNTHETIC BIOTIC MEDICINES TO SECRETE HUMAN PROTEINS AND SHORT CHAIN FATTY ACIDS AS A VERSATILE PLATFORM TO TREAT INFLAMMATORY BOWEL DISEASE
2022
·
Analise Z. Reeves
, Starsha Kolodziej
, et al.
·
Gastroenterology
·
2
Pd21-10 Safety and Tolerability of an Oxalate-consuming Synthetic Biotic Medicine: Synb8802 in Healthy Volunteers With Induced Dietary Hyperoxaluria
2021
·
Marja Puurunen
, William Denney
, et al.
·
The Journal of Urology
·
2
Engineered Escherichia coli Nissle 1917 for the prevention of uremic toxin accumulation in chronic kidney disease
2023
·
David Lubkowicz
·
Digital Repository Service (Northeastern University)
·
1
PDF
Proof-of-Concept Study of Oxalate-Consuming Synthetic Biotic Medicine SYNB8802 in Enteric Hyperoxaluria after Roux-en-Y Surgery
2021
·
Marja Puurunen
, William Denney
, et al.
·
Journal of the American Society of Nephrology
·
1
Development of a Synthetic Biotic, SYNB8802, for the Treatment of Enteric Hyperoxaluria
2020
·
Lauren Renaud
, David Lubkowicz
, et al.
·
Journal of the American Society of Nephrology
·
1
Synb1353, a Proposed Therapy for Homocystinuria, Lowers Plasma Methionine and Homocysteine in Healthy Volunteers Exposed to a Methionine Challenge
2023
·
Neal Sondheimer
, David Lubkowicz
, et al.
·
Molecular Genetics and Metabolism
Gastrointestinal Methionine Metabolism With Live Biotherapeutics Synb1353 Results in Improved Plasma Methionine and Homocysteine Levels in Mice and Nonhuman Primates
2023
·
Mylene Perreault
, Erik Gerson
, et al.
·
Molecular Genetics and Metabolism
Engineering and manufacturing of probiotic E. Coli to treat metabolic disorder
2019
·
Eugene Antipov
, Vincent M. Isabella
, et al.
Engineering of probiotic E.coli to treat metabolic disorders
2018
·
Paul S. Miller
, Vincent M. Isabella
, et al.
Genetically engineered probiotic E. coli Nissle to consume amino acids associated with orphan metabolic diseases
2018
·
Ning Li
, David Lubkowicz
, et al.
Show more works
View as search
Works count:
18
Citation count:
952
H-index:
7
I10-index:
7
Year
Topic
Type
